Why, when and how to initiate insulin therapy in patients with type 2 diabetes

International Journal of Clinical Practice

Volumn 61, Issue 4, 2007, Pages 633-644

  Tibaldi, J ^a,c   Rakel, R E ^b  

^a FLUSHING HOSPITAL MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; EXENDIN 4; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HUMAN INSULIN; INCRETIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; SITAGLIPTIN; SULFONYLUREA;

BOLUS INJECTION; CELL DAMAGE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; DIABETES CONTROL; DIABETIC PATIENT; DRUG DELIVERY SYSTEM; DRUG DOSE TITRATION; EARLY INTERVENTION; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN PUMP; INSULIN RESISTANCE; INSULIN TREATMENT; LOADING DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; VASCULAR DISEASE;

DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; PRACTICE GUIDELINES AS TOPIC;

EID: 33947408052     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01309.x     Document Type: Review

References (98)

1. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. National Diabetes Statistics: general information and national estimates on diabetes in the United States, 2005. NIH Publication No. 06-3892. http://diabetes.niddk.nih.gov/dm/pubs/statistics/index.htm 2005 (accessed on 4 August 2006).
2. Cowie CC, Rust KF, Byrd-Holt DD et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. Population: National Health and Nutrition Examination Survey 1999-2002. Diabetes Care 2006; 29: 1263-8.
3. Quest Diagnostics. Patients improved diabetes control over 5-year period, but many fail to achieve treatment goal. Quest Diagnostics Health Trends™ Diabetes Report is based on 14.3 million test results from 2001-2005 from the nation's largest database of clinical lab results. http://www.questdiagnostics. com/brand/business/healthtrends/diabetes/diabetesreport.html (accessed on 3 August 2006).
4. Saaddine JB, Cadwell B, Gregg EB et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med 2006; 144: 465-74.
5. Chan JL, Abrahamson MJ. Pharmacological management of type 2 diabetes mellitus: rationale for rational use of insulin. Mayo Clin Proc 2003; 78: 459-67.
6. Lebovitz HE. Insulin secretagogues: old and new. Diabetes Rev 1999; 7: 139-53.
7. Bergenstal RM, Kendall DM, Franz MJ, Rubenstein AH. Management of Type 2 diabetes: a systematic approach to meeting the standards of care: II oral agents, insulin, and management of complications. In: Degroot L, Jameson JL, eds. Endocrinology. Philadelphia, PA: W.B. Saunders Company, 2001: 821-35.
8. Palumbo PJ. The case for insulin treatment early in type 2 diabetes. Cleve Clin J Med 2004; 71: 385-2, 394.
9. U.K. Prospective Diabetes Study Group. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-58.
10. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
11. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
12. 1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995; 44: 968-83.
13. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963-72.
14. American Diabetes Association. American Diabetes Association (ADA) guidelines: clinical practice recommendations. Diabetes Care 2006; 29 (Suppl. 1): S1-85.
15. American Association of Clinical Endocrinologists. The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management-2002 update. Endocr Pract 2002; 8 (Suppl. 1): 40-82.
16. Davidson JA, Blonde L, Jellinger PS et al. Road map for the prevention and treatment of type 2 diabetes. ACE/AACE Diabetes Road Map Task Force. http://www.aace.com/meetings/consensus/odimplementation/roadmap.pdf (accessed on 1 August 2006).
17. Goyder EC, McNally PG, Drucquer M et al. Shifting of care for diabetes from secondary to primary care, 1990-5: review of general practices. BMJ 1998; 316: 1505-6.
18. Renders CM, Valk GD, Griffin SJ et al. Interventions to improve the management of diabetes in primary care, outpatient, and community settings: a systematic review. Diabetes Care 2001; 24: 1821-33.
19. Turner R, Stratton I, Horton V et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 1997; 350: 1288-93.
20. Landin-Olsson M. Latent autoimmune diabetes in adults. Ann N Y Acad Sci 2002; 958: 112-6.
21. Gleeson JM, Berenbeim DM, Gilkin RJ. Incretin mimetics: promising new therapeutic options in the treatment of type 2 diabetes. J Manag Care Pharm 2005; 11 (Suppl. 7): S2-15.
22. Earl MA. Emerging therapies in the treatment of type 2 diabetes. Pharmacother Update 2005; 8: http://www.clevelandclinicmeded.com/ medical_info/pharmacy/janfeb2005/type2.htm.
23. Wright A, Burden AC, Paisey RB et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002; 25: 330-6.
24. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003; 289: 2254-64.
25. Caumo A, Lauzi L. First-phase insulin secretion: does it exist in real life? Am J Physiol Endocrinol Metab 2004; 287: E371-85.
26. Hirsch IB. Insulin analogues. N Engl J Med 2005; 352: 174-83.
27. Vazquez-Carrera M, Silvestre JS. Insulin analogues in the management of diabetes. Methods Find Exp Clin Pharmacol 2004; 26: 445-61.
28. Brunton S, Carmichael B, Funnell M et al. Type 2 diabetes: the role of insulin. J Fam Pract 2005; 54 (5 Suppl.): 445-51.
29. Howey DC, Bowsher RR, Brunelle RL et al. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396-402.
30. Mudaliar SR, Lindberg FA, Joyce M et al. Insulin aspart (B28 aspinsulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999; 22: 1501-6.
31. Bastyr EJ III, Stuart CA, Brodows RG et al. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. Diabetes Care 2000; 23: 1236-41.
32. Brunelle RL, Llewelyn J, Anderson JH Jr et al. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 1998; 21: 1726-31.
33. Rolla AR, Rakel RE. Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues. Clin Ther 2005; 27: 1113-25.
34. Heinemann L, Linkeschova R, Rave K et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23: 644-9.
35. Rosenstock J, Schwartz SL, Clark CM Jr et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001; 24: 631-6.
36. Russell-Jones D, Simpson R, Hylleberg B et al. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 2004; 26: 724-36.
37. Haak T, Tiengo A, Draeger E et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005; 7: 56-64.
38. Raslova K, Bogoev M, Raz I et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes (Correction appears in Raslova K, et al. Diabetes Res Clin Pract 2006;72:112). Diabetes Res Clin Pract 2004; 66: 193-201.
39. Hermansen K, Davies M, Derezinski T et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29: 1269-74.
40. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-6.
41. Rosenstock J, Dailey G, Massi-Benedetti M et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005; 28: 950-5.
42. Rolla AR. Insulin analog mixes in the management of type 2 diabetes mellitus. Pract Diabetol 2002; 21: 36-44.
43. Roach P, Trautmann M, Arora V et al. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin-protamine formulations, insulin lispro Mix25. Clin Ther 1999; 21: 523-34.
44. Garber AJ. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs 2006; 66: 31-49.
45. Niskanen L, Jensen LE, Rastam J et al. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clin Ther 2004; 26: 531-40.
46. Christiansen JS, Vaz JA, Metelko Z et al. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes. Diabetes Obes Metab 2003; 5: 446-54.
47. Roach P, Woodworth JR. Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures. Clin Pharmacokinet 2002; 41: 1043-57.
48. Hermansen K, Colombo M, Storgaard H et al. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 2002; 25: 883-8.
49. Boehm BO, Home PD, Behrend C et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002; 19: 393-9.
50. Jacobsen LV, Sogaard B, Riis A. Comparison of the pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart and a similar premix of human insulin. Diabetes 1999; 48: A108 [Abstract].
51. Boehm B, Home P, Rastam J et al. Safety and efficacy of long term exposure to biphasic insulin aspart compared with biphasic human insulin in people with type 2 diabetes. Diabetologia 2003; 46 (Suppl. 2): A269.
52. Liebl A, Prager R, Kaiser M et al. Biphasic insulin aspart 30 (BIAsp30), insulin detemir (IDet) and insulin aspart (IAsp) allow patients with type 2 diabetes to reach A1C target: the PREFER study. Diabetes 2006; 55 (Suppl. 1): A123.
53. Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ 2006; 32: 9S-18S.
54. Korytkowski M, Niskanen L, Asakura T. FlexPen®: addressing issues of confidence and convenience in insulin delivery. Clin Ther 2005; 27 (Suppl. B): S89-100.
55. Asakura T, Seino H. Handling and safety of two insulin injection pens (FlexPen® and OptiClik®) in insulin-naive type 2 diabetes patients. Diabetes 2006; 55 (Suppl. 1): A457.
56. Pickup JC, Kidd J, Burmiston S et al. Determinants of glycaemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability. Diabetes Metab Res Rev 2006; 22: 232-7.
57. Siebenhofer A, Plank J, Berghold A et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2004; CD003287.
58. Retnakaran R, Hochman J, Devries JH et al. Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. Diabetes Care 2004; 27: 2590-6.
59. Davidson MB, Mehta AE, Siraj ES. Inhaled human insulin: an inspiration for patients with diabetes mellitus? Cleve Clin J Med 2006; 73: 569-78.
60. Nathan DM. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 2002; 347: 1342-9.
61. Genuth S. Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes. Endocr Pract 2006; 12 (Suppl. 1): 34-41.
62. Dailey G. New strategies for basal insulin treatment in type 2 diabetes mellitus. Clin Ther 2004; 26: 889-901.
63. Garvey WT, Olefsky JM, Griffin J et al. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 1985; 34: 222-34.
64. Alvarsson M, Sundkvist G, Lager I et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 2003; 26: 2231-7.
65. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-12.
66. Wild SH, Smith FB, Lee AJ et al. Criteria for previously undiagnosed diabetes and risk of mortality: 15-year follow-up of the Edinburgh Artery Study cohort. Diabet Med 2005; 22: 490-6.
67. Pibernik-Okanovic M, Szabo S, Metelko Z. Quality of life following a change in therapy for diabetes mellitus. Pharmacoeconomics 1998; 14: 201-7.
68. Oglesby AK, Secnik K, Barron J et al. The association between diabetes related medical costs and glycemic control: a retrospective analysis. Cost Eff Resour Alloc 2006; 4: 1.
69. Schwartz S, Sievers R, Strange P et al. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. Diabetes Care 2003; 26: 2238-43.
70. Menzin J, Langley-Hawthorne C, Friedman M et al. Potential short-term economic benefits of improved glycemic control: a managed care perspective. Diabetes Care 2001; 24: 51-5.
71. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-17.
72. Mayfield JA, White RD. Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. Am Fam Physician 2004; 70: 489-500.
73. Brunton SA, White JR Jr, Renda SM. The role of basal insulin in type 2 diabetes management. J Fam Pract 2005; (suppl.): S1-8.
74. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881-5.
75. Monnier L, Colette C, Monnier L et al. Contributions of fasting and postprandial glucose to hemoglobin A1c. Endocr Pract 2006; 12 (Suppl. 1): 42-6.
76. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 2005; 54: 1-7.
77. Raskin P, Allen E, Hollander P et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260-5.
78. Hirsch IB, Bergenstal RM, Parkin CG et al. A real-world approach to insulin therapy in primary care practice. Clin Diabetes 2005; 23: 78-86.
79. DeWitt DE, Dugdale DC. Using new insulin strategies in the outpatient treatment of diabetes: clinical applications. JAMA 2003; 289: 2265-9.
80. National Institute for Health and Clinical Excellence. Glitazones for the treatment of type 2 diabetes. http://www.nice.org.uk/page.aspx?o=83269. 2003 (accessed on 2 January 2007).
81. Huang A, Raskin P. Thiazolidinediones and insulin: rationale for use and role of combination therapy in type 2 diabetes mellitus. Treat Endocrinol 2005; 4: 205-20.
82. Garber AJ, Wahlen J, Wahl T et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (the 1-2-3 study). Diabetes Obes Metab 2006; 8: 58-66.
83. Davies M, Storms F, Shutler S et al. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005; 28: 1282-8.
84. Novo Nordisk Inc. Levemir® (Insulin Detemir [rDNA Origin] Injection) [Product Information]. Princeton, NJ: Novo Nordisk, 2005.
85. Fritsche A, Schweitzer MA, Haring HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003; 138: 952-9.
86. Standl E, Maxeiner S, Raptis S. Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility. Horm Metab Res 2006; 38: 172-7.
87. Philis-Tsimikas A, Charpentier G, Clauson P et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006; 28: 1569-81.
88. Lankisch M, Stahr B, Alawi H et al. Basal insulin and oral antihyperglycemic therapy (BOT) plus a single dose of insulin glulisine at breakfast or at the predominant meal lower HbA1c in patients with type 2 diabetes. Diabetes 2006; 55 (Suppl. 1): A122-3.
89. Bell DS, Clements RS Jr, Perentesis G et al. Dosage accuracy of self-mixed vs premixed insulin. Arch Intern Med 1991; 151: 2265-9.
90. Kann PH, Wascher T, Zackova V et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes 2006; 114: 527-32.
91. Malone JK, Kerr LF, Campaigne BN et al. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004; 26: 2034-44.
92. Malone JK, Bai S, Campaigne BN et al. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabet Med 2005; 22: 374-81.
93. Peyrot M, Rubin RR, Lauritzen T et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005; 28: 2673-9.
94. Korytkowski M, Bell D, Jacobsen C et al. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 2003; 25: 2836-48.
95. Boyle PJ, Zrebiec J. Management of diabetes-related hypoglycemia. South Med J 2007; 100(2): 183-94.
96. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res 1998; 6: 47-53.
97. Makimattila S, Nikkila K, Yki-Jarvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus. Diabetologia 1999; 42: 406-12.
98. Lebovitz HE. Therapeutic options in development for management of diabetes: pharmacologic agents and new technologies. Endocr Pract 2006; 12 (Suppl. 1): 142-7.